Original Article

MiR-21-5p Promotes Osteogenic Differentiation and Calcification of Valvular Interstitial Cells by Targeting TGFBI in Calcific Aortic Valve Disease

Abstract

Background: Calcific aortic valve disease (CAVD) is the most common heart relating disease with high morbidity and mortality, especially in elderly population. While extensive investigations have been devoted to the study of mechanistic pathways related to CAVD, the key factors and mechanisms mediating valve mineralization remain unclear. The aim of this study is to investigate the role of mirnas and their downstream targets in CAVD disease progression. A previous recent multi-omics study suggested a novel CAVD molecular interaction network contained miR-21-5p.
Methods: CAV and their pair-matched adjacent normal tissues were obtained from 15 patients pathologically diagnosed as CAVD and admitted in Yancheng Third People's Hospital (The Sixth Affiliated Hospital of Nantong University) from 2019-2021. RT-qPCR was utilized for detection of miR-21-5p and related protein expression levels to confirm the related factors in CAVD progression. Western blotting was applied to strengthen the results of RT-qPCR and confirm osteogenic differentiation of VICs via biomarker detection. The staining of alkaline phosphatase (ALP) and alizarin red was performed to assess the degree of VIC mineralization.
Results: We found that miR-21-5p was remarkably increased (P<0.0001) in calcified aortic valves (AVs) whereas TGFBI was diminished (P<0.01) in CAVD samples compared to the paired normal tissues from CAVD patients. Additionally, TGFBI was targeted by miR-21-5p. Furthermore, overexpressing TGFBI could block VIC osteogenic differentiation mediated by miR-21-5p. To sum up, miR-21-5p promotes VIC osteogenic differentiation and calcification via TGFBI in CAVD progression.
Conclusion:  Our work might bring a sight on underlying mechanisms of CAVD progression and provide a possible therapeutic target for diagnosis and treatment.

1. Nkomo VT, Gardin JM, Skelton TN, Gott-diener JS, Scott CG, Enriquez-Sarano M (2006). Burden of valvular heart diseases: a population-based study. Lancet, 368(9540):1005-11.
2. Kraler S, Blaser MC, Aikawa E, Camici GG, Lüscher TF (2022). Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J, 43(7):683-697.
3. Alushi B, Curini L, Christopher MR, et al (2020). Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies. Front Pharmacol, 11:685.
4. Mathieu P, Boulanger MC (2014). Basic Mechanisms of Calcific Aortic Valve Disease. Can J Cardiol, 30(9):982-93.
5. Ma X, Zhao D, Yuan P, et al (2020). Endo-thelial-to-Mesenchymal Transition in Calcific Aortic Valve Disease. Acta Car-diol Sin, 36(3):183-194.
6. Myasoedova VA, Ravani AL, Frigerio B, et al (2018). Novel pharmacological targets for calcific aortic valve disease: Preven-tion and Treatments. Pharmacol Res, 136:74-82.
7. Rutkovskiy A, Malashicheva A, Sullivan G, et al (2017). Valve Interstitial Cells: The Key to Understanding the Pathophysi-ology of Heart Valve Calcification. J Am Heart Assoc, 6(9):e006339.
8. Decano JL, Iwamoto Y, Goto S, et al (2022). A disease-driver population within inter-stitial cells of human calcific aortic valves identified via single-cell and pro-teomic profiling. Cell Rep, 39(2):110685.
9. Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA (2016). MicroRNAs in heart failure: from biomarker to tar-get for therapy. Eur J Heart Fail, 18(5):457-68.
10. Çakmak HA, Demir M (2020). MicroRNA and Cardiovascular Diseases. Balkan Med J, 37: 60–71.
11. Wojciechowska A, Braniewska A, Kozar-Kamińska K (2017). MicroRNA in car-diovascular biology and disease. Adv Clin Exp Med, 26(5):865-874.
12. Chen C, Liu S, Cao G, et al (2022). Cardio-protective Effect of Paeonol on Chron-ic Heart Failure Induced by Doxorubi-cin via Regulating the miR-21-5p/S-Phase Kinase-Associated Protein 2 Axis. Front Cardiovasc Med, 9:695004.
13. Ke X, Liao Z, Luo X, et al (2022). Endothe-lial colony-forming cell-derived exoso-mal miR-21-5p regulates autophagic flux to promote vascular endothelial repair by inhibiting SIPL1A2 in atherosclerosis. Cell Commun Signal, 20(1):30.
14. Ma S, Zhang A, Li X, et al (2020). MiR-21-5p regulates extracellular matrix degrada-tion and angiogenesis in TMJOA by tar-geting Spry1. Arthritis Res Ther, 22(1):99.
15. Heuschkel MA, Skenteris NT, Hutcheson JD, et al (2020). Integrative Multi-Omics Analysis in Calcific Aortic Valve Dis-ease Reveals a Link to the Formation of Amyloid-Like Deposits. Cells, 9(10):2164.
16. Yan L, Ma J, Wang Y, et al (2018). miR-21-5p induces cell proliferation by targeting TGFBI in non-small cell lung cancer cells. Exp Ther Med, 16(6):4655-4663.
17. Jiang R, Chen X, Ge S, et al (2021). MiR-21-5p Induces Pyroptosis in Colorectal Cancer via TGFBI. Front Oncol, 10:610545.
18. Zhang M, Liu X, Zhang X, et al (2014). Mi-croRNA-30b is a multifunctional regula-tor of aortic valve interstitial cells. J Thorac Cardiovasc Surg, 147(3):1073-1080.e2.
19. Yang L, Zhu X, Ni Y, et al (2020). Mi-croRNA-34c Inhibits Osteogenic Dif-ferentiation and Valvular Interstitial Cell Calcification via STC1-Mediated JNK Pathway in Calcific Aortic Valve Dis-ease. Front Physiol, 11:829.
20. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25(4):402-8.
21. Liu GX, Ma S, Li Y, et al (2018). Hsa-let-7c controls the committed differentiation of IGF-1-treated mesenchymal stem cells derived from dental pulps by tar-geting IGF-1R via the MAPK pathways. Exp Mol Med, 50(4):1-14.
22. Blaser MC, Kraler S, Lüscher TF, Aikawa E (2021). Multi-Omics Approaches to De-fine Calcific Aortic Valve Disease Path-ogenesis. Circ Res, 128(9):1371-1397.
23. Hjortnaes J, Goettsch C, Hutcheson JD, et al (2016). Simulation of early calcific aortic valve disease in a 3D platform: A role for myofibroblast differentiation. J Mol Cell Cardiol, 94:13-20.
24. Liu AC, Joag VR, Gotlieb AI (2007). The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol, 171(5):1407-18.
25. Schlotter F, Halu A, Goto S, et al (2018). Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aor-tic Valve and Reveals Networks Driving Disease. Circulation, 138(4):377-393.
26. Ruiz M, Toupet K, Maumus M, Rozier P, Jorgensen C, Noël D (2020). TGFBI se-creted by mesenchymal stromal cells ameliorates osteoarthritis and is detect-ed in extracellular vesicles. Biomaterials, 226:119544.
Files
IssueVol 53 No 10 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v53i10.16703
Keywords
Osteogenic differentiation Valvular interstitial cells Calcific aortic valve disease
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Gu Y, Chen R, Song J, Shi Z, Wu J, Chang H, Yuan C, Shi W, Zhang Y. MiR-21-5p Promotes Osteogenic Differentiation and Calcification of Valvular Interstitial Cells by Targeting TGFBI in Calcific Aortic Valve Disease. Iran J Public Health. 2024;53(10):2260-2270.